Australia's Invetech thrives on "taking ideas to the market"
This article was originally published in Clinica
Invetech is a growing southern hemisphere company that is equally comfortable serving clients in the northern hemisphere. CEO Fred Davis told Clinica what an Aus$40m company with greater international pretensions does to secure its next stage of growth. Ashley Yeo asked the questions
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.